By Evercyte GmbH
To get in touch with Evercyte GmbH, simply fill out the form below.
Subscribe to Supplier
Evercyte joins EU LIFESAVER project to study ‘hidden’ maternal and fetal health influences
Vienna, Austria: – Innovative biotech manufacturer Evercyte GmbH has joined a new pan-European project that aims to identify the hitherto hidden factors that affect maternal and fetal health.
The EU funded LIFESAVER project is focused on Living Impact on Fetal Evolution of a range of environmental and pharmacological factors. It is tasked with creating a valid scientific knowledge base for the developmental and implementation of regulatory approaches affecting maternal and fetal health.
In particular, it aims to generate and validate the effects data of potential environmental pollutants and pharmacological treatments for pregnant women, which are usually impossible to assess, due to lack of effecting measuring tools.
It is hoped that Evercyte’s world-class knowledge of standardized high-throughput in vitro bioassays based on telomerized cell lines and extracellular vesicles (EVs) can play a valuable role in diagnostics.
The project leading to the development of LIFESAVER has received funding from the European Union’s Horizon 2020 (H2020) research and innovation programme under grant agreement No 101036702.
Evercyte is the leading provider of immortalized human primary-like cells (‘telomerized cells’) as well as novel production cell lines for extracellular vesicles and is the partner of choice for innovative cell-based assays in the field of pharma, biotech, or cosmetic industries.
The core technology used for the establishment of these highly relevant human cell lines relies on the reactivation of the human telomerase enzyme. Besides customer-tailored cell line development as a one-stop shop, Evercyte is steadily expanding its catalog of readily available cell lines for the production of extracellular vesicles from mesenchymal stem cells using different tissues including Wharton’s Jelly, adipose tissue, bone marrow, and placenta.
By providing native extracellular vesicles from mesenchymal stem cells and targeting extracellular vesicles Evercyte will make a significant contribution to the development of new therapeutic approaches.
Founded in 2011, the Vienna-based company successfully pioneered the development of tools and know-how necessary for the establishment of standardized high-throughput in vitro bioassays as well as relevant cell models and cell factories.
Learn more at: http://www.evercyte.com.
Click on Evercyte proud to join LIFESAVER project to see original announcement.